Roche reported positive phase 3 results for sefaxersen in primary IgA nephropathy, supporting statistically significant and clinically meaningful improvements in proteinuria reduction versus placebo. The company positioned the data as potentially sufficient for an accelerated U.S. FDA filing. The development increases competitive pressure in a kidney disease market where multiple therapies are already approved and additional candidates are seeking differentiation on dosing, endpoints, and speed to access. As Roche and Ionis’ antisense platform approaches regulatory review, investors and clinicians will likely focus on the durability of proteinuria effects and the post-approval evidence path for accelerated approvals.